Annual Current Liabilities
$21.62 M
+$5.07 M+30.65%
December 31, 2023
Summary
- As of February 7, 2025, OLMA annual total current liabilities is $21.62 million, with the most recent change of +$5.07 million (+30.65%) on December 31, 2023.
- During the last 3 years, OLMA annual current liabilities has risen by +$17.04 million (+371.56%).
- OLMA annual current liabilities is now at all-time high.
Performance
OLMA Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$30.70 M
+$4.17 M+15.70%
September 30, 2024
Summary
- As of February 7, 2025, OLMA quarterly total current liabilities is $30.70 million, with the most recent change of +$4.17 million (+15.70%) on September 30, 2024.
- Over the past year, OLMA quarterly current liabilities has increased by +$14.73 million (+92.28%).
- OLMA quarterly current liabilities is now at all-time high.
Performance
OLMA Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
OLMA Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +30.6% | +92.3% |
| 3 y3 years | +371.6% | +92.3% |
| 5 y5 years | +10000.0% | +92.3% |
OLMA Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +139.7% | at high | +240.4% |
| 5 y | 5-year | at high | +1469.0% | at high | +2127.9% |
| alltime | all time | at high | >+9999.0% | at high | +2127.9% |
Olema Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $30.70 M(+15.7%) |
| Jun 2024 | - | $26.54 M(+1.2%) |
| Mar 2024 | - | $26.22 M(+21.3%) |
| Dec 2023 | $21.62 M(+30.6%) | $21.62 M(+35.4%) |
| Sep 2023 | - | $15.97 M(+7.7%) |
| Jun 2023 | - | $14.83 M(-23.6%) |
| Mar 2023 | - | $19.41 M(+17.3%) |
| Dec 2022 | $16.55 M | $16.55 M(+31.8%) |
| Sep 2022 | - | $12.55 M(+2.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $12.31 M(+21.0%) |
| Mar 2022 | - | $10.17 M(+12.7%) |
| Dec 2021 | $9.02 M(+96.7%) | $9.02 M(+1.3%) |
| Sep 2021 | - | $8.90 M(+9.3%) |
| Jun 2021 | - | $8.15 M(+54.4%) |
| Mar 2021 | - | $5.28 M(+15.1%) |
| Dec 2020 | $4.58 M(+232.7%) | $4.58 M(-13.0%) |
| Sep 2020 | - | $5.27 M(+282.7%) |
| Dec 2019 | $1.38 M(+585.6%) | $1.38 M |
| Dec 2018 | $201.00 K | - |
FAQ
- What is Olema Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for Olema Pharmaceuticals?
- What is Olema Pharmaceuticals annual current liabilities year-on-year change?
- What is Olema Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Olema Pharmaceuticals?
- What is Olema Pharmaceuticals quarterly current liabilities year-on-year change?
What is Olema Pharmaceuticals annual total current liabilities?
The current annual current liabilities of OLMA is $21.62 M
What is the all time high annual current liabilities for Olema Pharmaceuticals?
Olema Pharmaceuticals all-time high annual total current liabilities is $21.62 M
What is Olema Pharmaceuticals annual current liabilities year-on-year change?
Over the past year, OLMA annual total current liabilities has changed by +$5.07 M (+30.65%)
What is Olema Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of OLMA is $30.70 M
What is the all time high quarterly current liabilities for Olema Pharmaceuticals?
Olema Pharmaceuticals all-time high quarterly total current liabilities is $30.70 M
What is Olema Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, OLMA quarterly total current liabilities has changed by +$14.73 M (+92.28%)